Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07014618 · ClinicalTrials.gov registry record

Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer

A clinical trial of Breast Cancer and Prostate Cancer, sponsored by University of Oklahoma.

Recruiting
Registry status
420
Enrollment target
1
Study location

NCT07014618 is a study of Breast Cancer and Prostate Cancer that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 420 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07014618, a study of Breast Cancer and Prostate Cancer, is actively recruiting participants, sponsored by University of Oklahoma.

RECRUITING
Registry status
420 participants
Enrollment target
1
Study location

Study Summary

The purpose of this clinical trial is to evaluate radiation therapy (RT) completion rates among underrepresented cancer populations using qualitative measurements. Additionally, the study aims to assess the impact of patient navigators on supporting patients through their radiation care, as well as their influence on adherence to standard of care treatment modalities.

Interventions

  • OTHER Pre & Post Surveys
  • OTHER Opt Out of Questionnaire

Study Locations (1)

Oklahoma

  • OU Health Stephenson Cancer Center - Oklahoma City

Trial Details

FieldValue
Enrollment Target 420 participants
Start Date 2025-10-16
Est. Completion 2030-10

Sponsor

University of Oklahoma

358 total trials

What the Registry Record Tells You About NCT07014618

The ClinicalTrials.gov registry entry for NCT07014618 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (85% lower). The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pre & Post Surveys is the first listed.

NCT07014618 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.

Frequently Asked Questions

What is clinical trial NCT07014618 about?

NCT07014618 is a clinical study titled "Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer". The purpose of this clinical trial is to evaluate radiation therapy (RT) completion rates among underrepresented cancer populations using qualitative measurements. Additionally, the study aims to assess the impact of patient navigators on supporting patients through their radiation care, as well as ...

What is the current status of trial NCT07014618?

This trial is currently recruiting. The enrollment target is 420 participants. The study started on 2025-10-16. Estimated completion is 2030-10.

What conditions does trial NCT07014618 study?

This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer.

What interventions are being tested in trial NCT07014618?

The interventions under investigation include: Pre & Post Surveys (OTHER), Opt Out of Questionnaire (OTHER).

Who is sponsoring clinical trial NCT07014618?

This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07014618 being conducted?

This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.